Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.

NCT02014337 is registered in ClinicalTrials.gov with Corcept Therapeutics as lead sponsor.

NCT NCT02014337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02014337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.
Lead sponsor
Corcept Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2014
Completion date
December 31, 2017
Enrollment
37 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, carcinoma, transitional cell, non-small cell lung cancer, ovarian epithelial cancer recurrent, prostate cancer, prostatic neoplasms, sarcoma